Alliance Continued on Point-of-Care Testing

An alliance to develop improved products for hospital point-of-care (POC) testing is being continued, according to the principals, Bayer Diagnostics (Tarrytown, NY, USA) and Igen International (Gaithersburg, MD, USA). Based on the progress made to date, Bayer will provide additional funds, which will be focused on the development of a marketing strategy and product design.

The product design is to be based on Igen's Tricorder diagnostic detection module and Bayer's clinical products. The Tricorder module incorporates proprietary Origen technology, which can assay a wide range of biologic substances, including small molecules, proteins, nucleic acids, and microorganisms with sensitivity, reliability, speed, and flexibility. This results in high-value clinical testing that includes immunodiagnostic and nucleic acid probe-based measurements. POC testing is one of the fastest growing areas of the clinical diagnostics market.

"Our collaboration is focused on product solutions that are integrated and networked, providing the right information at the right time to operating rooms, CCU/ICU, emergency rooms, and other POC locations,” said Fran Tuttle, senior vice president of near patient testing for Bayer Diagnostics.



Related Links:
Bayer Diagnostics
Igen